Emverm (mebendazole)

No dosing information is available for this tab.

Mebendazole is administered orally and may be taken without regard to meals.

Mebendazole 100-mg chewable tablets may be chewed, swallowed whole, or crushed and mixed with food.

Mebendazole 500-mg chewable tablets must be chewed completely before swallowing and should not be swallowed whole. In individuals who have difficulty chewing, the 500-mg tablet should be placed on a spoon and about 2-3 mL of drinking water added onto the tablet using a dosing syringe; within 2 minutes, the tablet should absorb the water and change into a soft, semi-solid mass that can be swallowed.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

In rat reproduction studies, adverse developmental effects (i.e., skeletal malformations, soft tissue malformations, decreased pup weight, embryolethality) were observed when a single oral dose of mebendazole as low as 10 mg/kg (about 0.2 times the total maximum daily human dosage) was administered during the period of organogenesis. Maternal toxicity was reported at higher dosages.

Published data to date regarding use of mebendazole in pregnant women (e.g., prospective pregnancy registries, case-control retrospective cohort studies, randomized controlled studies) have not indicated a clear association between mebendazole and a potential risk of major birth defects or miscarriage. Overall, these studies did not identify a specific pattern or frequency of major birth defects with mebendazole use. However, these studies cannot definitely establish the absence of any mebendazole-associated risk because of methodological limitations, including recall bias, confounding factors, and, in some cases, small sample size or exclusion of first-trimester mebendazole exposures.

Clinicians should consider that untreated soil-transmitted helminth infections in pregnancy can be associated with adverse outcomes, including maternal iron deficiency anemia, low birthweight, and neonatal and maternal death.

Limited data indicate that mebendazole is distributed into milk in low concentrations following oral administration. Effects of the drug on human milk production and effects on the breast-fed infant are unknown.

The benefits of breast-feeding and the importance of mebendazole to the woman should be considered along with potential adverse effects on the breast-fed child from the drug or from the underlying maternal condition.

No enhanced messaging available.